-
Product Insights
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Esophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophageal Squamous Cell Carcinoma (ESCC) - Drugs In Development, 2023’, provides an overview of the Esophageal Squamous Cell Carcinoma (ESCC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Squamous Cell Carcinoma (ESCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Brain Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Brain Cancer - Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroblastoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroblastoma - Drugs In Development, 2023’, provides an overview of the Neuroblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olutasidenib in Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olutasidenib in Glioma Drug Details: Olutasidenib (Rezlidhia) is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Adagloxad Simolenin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adagloxad Simolenin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Adagloxad Simolenin in Triple-Negative Breast Cancer (TNBC) Drug Details:Adagloxad simolenin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TH-3424 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TH-3424 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TH-3424 in T-Cell Acute Lymphocytic Leukemia (T-Cell...
-
Sector Analysis
Hungary Retail Market Size by Sector and Channel Including Online Retail, Key Players and Forecast to 2027
Hungary Retail Market Report Overview The Hungary retail market size was HUF 14,289 billion in 2022. The market is expected to grow at a CAGR of more than 7% during 2022-2027. The Hungary retail market research report provides both historic and forecast market data for total retail sales in Hungary. Hungary Retail Market Outlook, 2022 - 2027 (HUF Billion) Buy Full Report for More Insights into the Hungary Retail Market Forecast Download A Free Report Sample The report illustrates the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R3R-01 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R3R-01 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.R3R-01 in Focal Segmental Glomerulosclerosis (FSGS)Drug Details:R3R-01 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azenosertib in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Epithelial Ovarian CancerDrug Details:Azenosertib (ZNC-3) is under development for the...